Oral Thin Films

Oral Thin Films

Global Oral Thin Films Market to Reach US$9.5 Billion by 2030

The global market for Oral Thin Films estimated at US$4.2 Billion in the year 2023, is expected to reach US$9.5 Billion by 2030, growing at a CAGR of 12.3% over the analysis period 2023-2030. Sublingual Film, one of the segments analyzed in the report, is expected to record a 11.7% CAGR and reach US$3.9 Billion by the end of the analysis period. Growth in the Fast Dissolving Dental/Buccal Film segment is estimated at 12.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 11.8% CAGR

The Oral Thin Films market in the U.S. is estimated at US$1.1 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 11.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.6% and 10.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.8% CAGR.

Global Oral Thin Films Market - Key Trends & Drivers Summarized

Why Are Oral Thin Films Gaining Popularity as a Novel Drug Delivery System?

Oral thin films (OTFs) are gaining popularity as a novel drug delivery system due to their ability to provide rapid onset of action, improved patient compliance, and enhanced bioavailability of active pharmaceutical ingredients (APIs). These films are thin, flexible strips that dissolve quickly upon contact with saliva, allowing the drug to be absorbed directly through the oral mucosa or gastrointestinal tract. Oral thin films offer several advantages over traditional oral dosage forms such as tablets and capsules, including ease of administration without the need for water, which is particularly beneficial for pediatric, geriatric, and dysphagic (difficulty swallowing) patients. Additionally, the quick-dissolving nature of OTFs ensures that the medication reaches systemic circulation faster, leading to a quicker onset of therapeutic effects.

OTFs are used to deliver a wide range of active ingredients, including analgesics, antiemetics, antipsychotics, and nutraceuticals. The ability to provide precise dosing and reduce the risk of choking or aspiration makes oral thin films an attractive option for delivering medications to vulnerable patient populations. Furthermore, OTFs can be designed to incorporate taste-masking agents, making them more palatable and increasing patient acceptance. The flexibility in formulation and ease of manufacturing also make OTFs suitable for both prescription and over-the-counter (OTC) products. As the pharmaceutical industry continues to focus on developing patient-centric drug delivery systems, the demand for oral thin films that offer convenience, efficacy, and compliance is expected to rise significantly.

How Are Technological Advancements Transforming the Oral Thin Films Market?

Technological advancements are transforming the oral thin films market by enabling the development of more sophisticated formulations, enhanced drug stability, and improved manufacturing processes. One of the most significant innovations in this space is the use of nanotechnology and microencapsulation techniques to improve the solubility and bioavailability of poorly water-soluble drugs. Nanoparticles and lipid-based carriers can be incorporated into the film matrix to enhance drug absorption through the oral mucosa, leading to increased efficacy and reduced dosage requirements. These technologies are particularly beneficial for drugs with low bioavailability or those that are sensitive to the acidic environment of the stomach, as they enable the drug to bypass the gastrointestinal tract and enter systemic circulation more directly.

Another transformative trend is the development of multi-layered and multi-compartment oral thin films that allow for the controlled release of multiple active ingredients. By using advanced film-forming techniques, manufacturers can create films with distinct layers that dissolve at different rates, providing immediate and sustained release profiles within a single dosage form. This capability is ideal for combination therapies where the simultaneous or sequential release of different drugs is required. The use of microprinting technology is also gaining traction in the production of OTFs, as it allows for precise placement of active ingredients on the film surface, ensuring uniform drug distribution and dosage accuracy.

The integration of taste-masking technologies is further enhancing the appeal of oral thin films, particularly for pediatric and geriatric applications. Taste-masking agents such as cyclodextrins, ion-exchange resins, and polymer coatings are used to encapsulate bitter-tasting drugs, making the films more palatable. This increases patient acceptance and compliance, especially in populations that are sensitive to unpleasant tastes. Moreover, advancements in film-forming polymers and excipients are improving the mechanical properties, stability, and dissolution rates of oral thin films, making them suitable for a wider range of therapeutic applications. As these technologies continue to evolve, they are making oral thin films a versatile and effective drug delivery platform that addresses the limitations of traditional oral dosage forms.

What Role Do Patient Compliance and Convenience Play in Driving the Adoption of Oral Thin Films?

Patient compliance and convenience are playing a pivotal role in driving the adoption of oral thin films as they offer a more user-friendly alternative to conventional dosage forms. Compliance is a significant concern in drug therapy, particularly for chronic conditions where long-term adherence to medication regimens is required. Factors such as difficulty swallowing pills, unpleasant taste, and the need for water can hinder patient compliance, leading to suboptimal therapeutic outcomes. Oral thin films address these challenges by providing a dosage form that dissolves quickly in the mouth without the need for water, making it easier for patients to take their medication discreetly and at any time. This is especially advantageous for patients with dysphagia, such as the elderly or those with neurological conditions, who may have difficulty swallowing tablets or capsules.

The ease of administration and portability of oral thin films also contribute to their growing popularity. Unlike traditional solid dosage forms, OTFs can be carried conveniently and do not require special storage conditions, making them ideal for on-the-go use. The ability to administer medication without water is beneficial in situations where water is not readily available, such as during travel or in outdoor settings. These attributes are making oral thin films an appealing option for pediatric patients who may resist taking traditional forms of medicine and for individuals with busy lifestyles who seek convenient medication options.

Additionally, the flexibility in dosing and formulation is supporting the use of oral thin films in personalized medicine. OTFs can be manufactured to deliver low doses of potent drugs or modified to provide controlled release profiles, allowing for customized therapies that meet the specific needs of individual patients. The use of OTFs in therapeutic areas such as pain management, antiemetics, and central nervous system (CNS) disorders is growing as these conditions often require rapid onset of action and patient-friendly dosage forms. As the healthcare industry continues to focus on improving patient adherence and outcomes, the demand for oral thin films that provide convenience, efficacy, and compliance is expected to increase significantly.

What Factors Are Driving the Growth of the Global Oral Thin Films Market?

The growth in the global oral thin films market is driven by several factors, including the increasing prevalence of chronic diseases, the rising demand for patient-friendly drug delivery systems, and ongoing technological advancements in formulation and manufacturing. One of the primary growth drivers is the growing prevalence of chronic conditions such as diabetes, cardiovascular diseases, and neurological disorders, which require long-term medication adherence. Oral thin films offer an innovative solution for delivering medications to these patient populations, providing a convenient and easy-to-administer dosage form that improves compliance. The use of OTFs in conditions like migraine, motion sickness, and anxiety, where rapid onset of action is crucial, is further boosting their adoption.

The rising demand for patient-friendly drug delivery systems is another key factor contributing to market growth. As healthcare becomes more patient-centric, pharmaceutical companies are focusing on developing dosage forms that cater to the needs of different patient groups, including children, the elderly, and individuals with swallowing difficulties. Oral thin films, with their non-invasive nature and ease of use, are gaining traction as they eliminate the challenges associated with swallowing and provide a more comfortable and acceptable alternative to tablets, capsules, and injections. The use of OTFs in pediatric and geriatric formulations is particularly significant, as these populations often have difficulty adhering to traditional medication regimens.

Ongoing technological advancements in formulation and manufacturing are also driving the growth of the oral thin films market. Innovations such as 3D printing, hot-melt extrusion, and electrospinning are enabling the production of oral thin films with enhanced mechanical properties, uniform drug distribution, and tailored dissolution profiles. These technologies are making it possible to develop OTFs for a wider range of therapeutic areas, including those that require complex drug delivery solutions. The ability to incorporate poorly soluble drugs, achieve controlled release, and ensure stability under varying environmental conditions is expanding the application scope of oral thin films and attracting interest from pharmaceutical companies seeking to differentiate their products.

Moreover, the increasing focus on developing over-the-counter (OTC) and nutraceutical oral thin films is creating new opportunities for the market. OTFs are being used to deliver vitamins, dietary supplements, and other nutraceuticals, providing a convenient and appealing dosage form for health-conscious consumers. The use of OTFs in smoking cessation therapies, weight management, and energy supplements is also growing, as these products benefit from the rapid absorption and convenience offered by oral thin films. The rising consumer preference for fast-dissolving and discreet dosage forms is supporting the expansion of OTFs into the nutraceutical and wellness sectors.

Additionally, the growing awareness and acceptance of oral thin films in emerging markets are contributing to market growth. Countries in Asia-Pacific, Latin America, and the Middle East are witnessing increased demand for innovative drug delivery systems as healthcare access improves and patient expectations evolve. The use of oral thin films in these regions is being supported by initiatives to improve medication adherence and expand access to pediatric and geriatric care. The relatively low manufacturing costs and ease of distribution of OTFs are making them an attractive option for pharmaceutical companies looking to enter or expand in these markets.

Furthermore, the impact of the COVID-19 pandemic has highlighted the need for patient-friendly, self-administered dosage forms that reduce the need for healthcare facility visits. Oral thin films, with their ease of use and ability to deliver medications for chronic conditions, pain relief, and mental health management, have seen increased interest during the pandemic. This trend is expected to continue as healthcare providers and patients seek safer and more convenient medication options. As these factors converge, the global oral thin films market is poised for robust growth, driven by technological advancements, evolving consumer preferences, and the increasing focus on patient-centric drug delivery solutions across various therapeutic areas.

Select Competitors (Total 48 Featured) -

• Allergan plc
• Aquestive Therapeutics Inc.
• Indivior plc
• IntelGenx Corp.
• LTS Lohmann Therapie-Systeme AG
• Mylan NV
• NAL Pharma
• Novartis AG
• Pfizer, Inc.
• Solvay
• Sumitomo Dainippon Pharma Co., Ltd.
• ZIM Laboratories Limited

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.